Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216

Press/Media: Press / Media

PeriodMar 3 2021

Media coverage

10

Media coverage

  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletFinanzen.net
    CountryGermany
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletYahoo! Finance
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletTD Ameritrade
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletMarkets Business Insider
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletTickerTech.com
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletProfitQuotes.com
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletKPVI
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletStar Local Media
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletTyler Morning Telegraph
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas
  • TitleDialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
    Media name/outletKilleen Daily Herald
    CountryUnited States
    Date3/3/21
    PersonsRobert A Hromas